You are here: Home / Protocols / Pancreatic Reference Set Application: Kazufumi Honda-National Cancer Center (2014)

Pancreatic Reference Set Application: Kazufumi Honda-National Cancer Center (2014)

392
Feng, ZidingFred Hutchinson Cancer Research Center
CA19-9, AT, ATQ
Proteomics
G.I. and Other Associated Cancers Research Group

Among human malignancies, invasive ductal adenocarcinoma of the pancreas has the worst prognosis,with a 5-year survival rate of less than 10%. Most patients with early stage pancreatic cancer have no clinical symptoms; therefore, many of them develop progressive disease that is not detected until the late stage. To improve the survival rate of pancreatic cancer, non-invasive diagnostic methods that detect the disease in its early stage must be developed.

To improve the survival rate of pancreatic cancer, non-invasive diagnostic methods that detect the disease in its early stage must be developed.
The National Cancer Institute (NCI) will send the pancreatic cancer reference serum samples to the National Cancer Center, and the National Cancer Center (NCC) will then blindly measure the levels of apoAII isoforms in the reference samples. NCC will return the data obtained from the reference set, and the NCI will subsequently calculate sensitivity, specificity, and the AUC. In addition, the NCI will evaluate the clinical utility for early detection of pancreatic cancer

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 09/27/2019
Thank you to everyone who made the 11th EDRN Scientific Workshop a success. The next EDRN Steering Committee Meeting is from Tuesday-Thursday, March 31-April 2, 2020 in Tempe, AZ.
Announcement



 
This icon signifies that something is happening and we kindly ask you to please wait